Citations (208)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Xiaojia Zuo & Dingsheng Liu. (2022) Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma. Hematology 27:1, pages 1110-1121.
Read now
Read now
Haiyu Niu, Feixue Song, Hanwen Wei, Yuan Li, Hao Huang & Changping Wu. (2021) Inhibition of BRD4 Suppresses the Growth of Esophageal Squamous Cell Carcinoma. Cancer Investigation 39:10, pages 826-841.
Read now
Read now
Orlando Morales-Tarré, Ramiro Alonso-Bastida, Bolivar Arcos-Encarnación, Leonor Pérez-Martínez & Sergio Encarnación-Guevara. (2021) Protein lysine acetylation and its role in different human pathologies: a proteomic approach. Expert Review of Proteomics 18:11, pages 949-975.
Read now
Read now
Natalie Cheng Chen, Gautam Borthakur & Naveen Pemmaraju. (2021) Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leukemia & Lymphoma 62:3, pages 528-537.
Read now
Read now
Xiuzuo Zhu, Yi Liao & Liling Tang. (2020) Targeting BRD9 for Cancer Treatment: A New Strategy. OncoTargets and Therapy 13, pages 13191-13200.
Read now
Read now
Nada Ahmed & Andrew L. Feldman. (2020) Targeting epigenetic regulators in the treatment of T-cell lymphoma. Expert Review of Hematology 13:2, pages 127-139.
Read now
Read now
Anneke D. van Dijk, Eveline S. J. M. de Bont & Steven M. Kornblau. (2020) Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. Expert Review of Proteomics 17:1, pages 1-10.
Read now
Read now
Tian Lu, Wenchao Lu & Cheng Luo. (2020) A patent review of BRD4 inhibitors (2013-2019). Expert Opinion on Therapeutic Patents 30:1, pages 57-81.
Read now
Read now
Lusy Handoko, Bogumil Kaczkowski, Chung-Chau Hon, Marina Lizio, Masatoshi Wakamori, Takayoshi Matsuda, Takuhiro Ito, Prashanti Jeyamohan, Yuko Sato, Kensaku Sakamoto, Shigeyuki Yokoyama, Hiroshi Kimura, Aki Minoda & Takashi Umehara. (2018) JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states. Epigenetics 13:4, pages 410-431.
Read now
Read now
Manel Esteller. (2017) Epigenetic drugs: More than meets the eye. Epigenetics 12:5, pages 307-307.
Read now
Read now
Articles from other publishers (198)
Soumen Barman, Ishita Bardhan, Jyotirmayee Padhan & Babu Sudhamalla. (2024) Integrated virtual screening and MD simulation approaches toward discovering potential inhibitors for targeting BRPF1 bromodomain in hepatocellular carcinoma. Journal of Molecular Graphics and Modelling 126, pages 108642.
Crossref
Crossref
Sabyasachi Banerjee, Sougata Mukherjee, Priyobrata Nath, Agnish Mukherjee, Souvik Mukherjee, S.K. Ashok Kumar, Sourav De & Subhasis Banerjee. (2023) A critical review of benzimidazole: Sky-high objectives towards the lead molecule to predict the future in medicinal chemistry. Results in Chemistry 6, pages 101013.
Crossref
Crossref
Parul Ahuja, Ritu Yadav, Sandeep Goyal, Chetna Yadav, Shalu Ranga & Lokesh Kadian. (2023) Targeting epigenetic deregulations for the management of esophageal carcinoma: recent advances and emerging approaches. Cell Biology and Toxicology 39:6, pages 2437-2465.
Crossref
Crossref
Ashraf Mohammed, M. Brett Waddell, Ieva Sutkeviciute, Adithi Danda, Steven J. Philips, Walter Lang, P. Jake Slavish, Sandra J. Kietlinska, Mangesh Kaulage, Das Sourav & Aseem Z. Ansari. (2023) Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions. Journal of the American Chemical Society.
Crossref
Crossref
Abhishek Wahi, Namish Manchanda, Priti Jain & Hemant R Jadhav. (2023) Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer. Bioorganic Chemistry 140, pages 106833.
Crossref
Crossref
Vindhya Vikram Singh & Shafqat Alauddin. (2023) Review on: BRD4 inhibitors for anticancer research. Human Gene 37, pages 201196.
Crossref
Crossref
Tingxun Lu, Jie Zhang, Zijun Y. Xu-Monette & Ken H. Young. (2023) The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Experimental Hematology & Oncology 12:1.
Crossref
Crossref
Muqing Li, Mingyu Liu, Wanting Han, Zifeng Wang, Dong Han, Susan Patalano, Jill A. Macoska, Steven P. Balk, Housheng Hansen He, Eva Corey, Shuai Gao & Changmeng Cai. (2023) LSD1 Inhibition Disrupts Super-Enhancer–Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Cancer Research 83:10, pages 1684-1698.
Crossref
Crossref
Vanessa Ortiz-Barahona, Marta Soler, Veronica Davalos, Carlos A. García-Prieto, Maxime Janin, Fernando Setien, Irene Fernández-Rebollo, Joan J. Bech-Serra, Carolina De La Torre, Sonia Guil, Alberto Villanueva, Pei-Hong Zhang, Li Yang, Marco Guarnacci, Ulrike Schumann, Thomas Preiss, Ugne Balaseviciute, Robert Montal, Josep M. Llovet & Manel Esteller. (2023) Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer. Molecular Cancer 22:1.
Crossref
Crossref
Luke A. Adams, Lorna E. Wilkinson-White, Menachem J. Gunzburg, Stephen J. Headey, Biswaranjan Mohanty, Martin J. Scanlon, Ben Capuano, Joel P. Mackay & Bradley C. Doak. (2023) Rapid Elaboration of Fragments into Leads Applied to Bromodomain-3 Extra-Terminal Domain. Journal of Medicinal Chemistry 66:8, pages 5859-5872.
Crossref
Crossref
Guoqing Luo, Bohao Liu, Tinglv Fu, Yi Liu, Boyang Li, Ning Li & Qing Geng. (2023) The Role of Histone Deacetylases in Acute Lung Injury—Friend or Foe. International Journal of Molecular Sciences 24:9, pages 7876.
Crossref
Crossref
Shahrzad S. Fard, Shaghayegh Kouchaki, Zahra Salimian, Masoud Sotoudeh, Seyed A. Mousavi, Kamran Alimoghaddam & Seyed H. Ghaffari. (2023) Overexpression of Bromodomain and Extraterminal Domain is Associated with
Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and
Therapeutic Value of the BET Protein Family in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry 23:7, pages 794-806.
Crossref
Crossref
Karen E. Ross, Guolin Zhang, Cuneyt Akcora, Yu Lin, Bin Fang, John Koomen, Eric B. Haura & Mark Grimes. (2023) Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer. PLOS Computational Biology 19:3, pages e1010690.
Crossref
Crossref
Deborah Gargano, Marco Segatto & Sabrina Di Bartolomeo. (2023) Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy. International Journal of Molecular Sciences 24:6, pages 5665.
Crossref
Crossref
Nizar Lefi, Aleksandr S. Kazachenko, Murugesan Raja, Noureddine Issaoui & Anna S. Kazachenko. (2023) Molecular Structure, Spectral Analysis, Molecular Docking and Physicochemical Studies of 3-Bromo-2-hydroxypyridine Monomer and Dimer as Bromodomain Inhibitors. Molecules 28:6, pages 2669.
Crossref
Crossref
Noemi Martella, Daniele Pensabene, Michela Varone, Mayra Colardo, Michele Petraroia, William Sergio, Piergiorgio La Rosa, Sandra Moreno & Marco Segatto. (2023) Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation. Biomedicines 11:3, pages 750.
Crossref
Crossref
Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer & Michael Dickinson. (2023) A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research 29:4, pages 711-722.
Crossref
Crossref
Masaru Ueno. (2023) Exploring Genetic Interactions with Telomere Protection Gene pot1 in Fission Yeast. Biomolecules 13:2, pages 370.
Crossref
Crossref
Junmin Dong & Xinghe Wang. (2023) Identification of novel BRD4 inhibitors by pharmacophore screening, molecular docking, and molecular dynamics simulation. Journal of Molecular Structure 1274, pages 134363.
Crossref
Crossref
Ester Colarusso, Sara Ceccacci, Maria Chiara Monti, Erica Gazzillo, Assunta Giordano, Maria Giovanna Chini, Maria Grazia Ferraro, Marialuisa Piccolo, Dafne Ruggiero, Carlo Irace, Stefania Terracciano, Ines Bruno, Giuseppe Bifulco & Gianluigi Lauro. (2023) Identification of 2,4,5-trisubstituted-2,4-dihydro-3H-1,2,4-triazol-3-one-based small molecules as selective BRD9 binders. European Journal of Medicinal Chemistry 247, pages 115018.
Crossref
Crossref
Vittoria Graziani, Aida Rodriguez Garcia, Lourdes Sainero Alcolado, Adrien Le Guennec, Marie Arsenian Henriksson & Maria R. Conte. (2023) Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition. Scientific Reports 13:1.
Crossref
Crossref
Yogita Yadav, Soumen Barman, Anirban Roy, Jyotirmayee Padhan & Babu Sudhamalla. (2022) Uncovering the Domain-Specific Interactome of the TAF1 Tandem Reader Using Site-Specific Azide-Acetyllysine Photochemistry. Biochemistry 62:2, pages 270-280.
Crossref
Crossref
Tiina Viita & Jacques Côté. (2023) The MOZ-BRPF1 acetyltransferase complex in epigenetic crosstalk linked to gene regulation, development, and human diseases. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Asmita Parab, Lokesh Kumar Bhatt & Abdelwahab Omri. (2023) Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy. Biomedicines 11:1, pages 169.
Crossref
Crossref
Patrycja Czerwinska & Andrzej Adam Mackiewicz. (2023) Bromodomain (BrD) Family Members as Regulators of Cancer Stemness—A Comprehensive Review. International Journal of Molecular Sciences 24:2, pages 995.
Crossref
Crossref
DoYeong Jeon, Nackhyoung Kim & Soo-Jong Um. (2023) BET Inhibitors Induce p53-Independent Growth Arrest in HCT116 Cells <i>via</i> Epigenetic Control of the E2F1/c-<i>MYC</i> Axis. Biological and Pharmaceutical Bulletin 46:1, pages 12-18.
Crossref
Crossref
Mengyuan Ding, Yingying Shao, Danwen Sun, Suorina Meng, Yi Zang, Yubo Zhou, Jia Li, Wei Lu & Shulei Zhu. (2023) Design, synthesis, and biological evaluation of BRD4 degraders. Bioorganic & Medicinal Chemistry 78, pages 117134.
Crossref
Crossref
Fumiaki Uchiumi. 2023. Bidirectional Gene Promoters. Bidirectional Gene Promoters
123
139
.
Krishna Mohan Poluri, Khushboo Gulati, Deepak Kumar Tripathi & Nupur NagarKrishna Mohan Poluri, Khushboo Gulati, Deepak Kumar Tripathi & Nupur Nagar. 2023. Protein-Protein Interactions. Protein-Protein Interactions
43
100
.
Mohsen Karami Fath, Ali Azargoonjahromi, Arash Kiani, Fateme Jalalifar, Parisa Osati, Mahsa Akbari Oryani, Fateh Shakeri, Farhad Nasirzadeh, Behman Khalesi, Mohsen Nabi-Afjadi, Hamidreza Zalpoor, Maysam Mard-Soltani & Zahra Payandeh. (2022) The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cellular & Molecular Biology Letters 27:1.
Crossref
Crossref
Liya Ma, Gen Li, Tianquan Yang, Li Zhang, Xinxin Wang, Xiaowen Xu & Hong Ni. (2022) An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16. Cancer Chemotherapy and Pharmacology 90:6, pages 431-444.
Crossref
Crossref
Artem Baranovskii, Irem B. Gündüz, Vedran Franke, Bora Uyar & Altuna Akalin. (2022) Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction. Cancers 14:22, pages 5604.
Crossref
Crossref
İlayda Alcitepe, Hilal Salcin, İlknur Karatekin & Burcin Tezcanli Kaymaz. (2022) HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents’ combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model. Medical Oncology 39:12.
Crossref
Crossref
Soumen Barman, Anirban Roy, Jyotirmayee Padhan & Babu Sudhamalla. (2022) Molecular Insights into the Recognition of Acetylated Histone Modifications by the BRPF2 Bromodomain. Biochemistry 61:17, pages 1774-1789.
Crossref
Crossref
Margarita E. Neganova, Sergey G. Klochkov, Yulia R. Aleksandrova & Gjumrakch Aliev. (2022) Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology 83, pages 452-471.
Crossref
Crossref
Haixiang Pei, Weikai Guo, Yangrui Peng, Hai Xiong & Yihua Chen. (2022) Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Medicinal Research Reviews 42:4, pages 1607-1660.
Crossref
Crossref
Liwen Hua, Qiuyue Zhang, Xinyue Zhu, Ruoning Wang, Qidong You & Lei Wang. (2022) Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. Journal of Medicinal Chemistry 65:12, pages 8091-8112.
Crossref
Crossref
Nanda Kumar Yellapu, Thuc Ly, Mihaela E. Sardiu, Dong Pei, Danny R. Welch, Jeffery A. Thompson & Devin C. Koestler. (2022) Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer. BMC Cancer 22:1.
Crossref
Crossref
Patrycja Czerwinska, Anna Maria Jaworska, Nikola Agata Wlodarczyk, Małgorzata Cisek, Marianna Karwacka, Julia Lipowicz, Julia Ostapowicz, Monika Rosochowicz & Andrzej Adam Mackiewicz. (2022) The association between bromodomain proteins and cancer stemness in different solid tumor types. International Journal of Cancer 150:11, pages 1838-1849.
Crossref
Crossref
Adonis Sfera, Karina G. Thomas, Christina V. Andronescu, Nyla Jafri, Dan O. Sfera, Sarvin Sasannia, Carlos M. Zapata-Martín del Campo & Jose C. Maldonado. (2022) Bromodomains in Human-Immunodeficiency Virus-Associated Neurocognitive Disorders: A Model of Ferroptosis-Induced Neurodegeneration. Frontiers in Neuroscience 16.
Crossref
Crossref
Swagata Adhikari, Apoorva Bhattacharya, Santanu Adhikary, Vipin Singh, Shrikanth S. GadadSiddhartha Roy & Chandrima Das. (2022) The paradigm of drug resistance in cancer: an epigenetic perspective. Bioscience Reports 42:4.
Crossref
Crossref
Juncheng Chen, Pan Tang, Yuxi Wang, Jiaxing Wang, Chengcan Yang, Yang Li, Gaoxia Yang, Fengbo Wu, Jifa Zhang & Liang Ouyang. (2022) Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. Journal of Medicinal Chemistry 65:7, pages 5184-5211.
Crossref
Crossref
Hafiz Akbar Ali, Yalan Li, Akram Hafiz Muhammad Bilal, Tingting Qin, Ziqiao Yuan & Wen Zhao. (2022) A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles. Frontiers in Pharmacology 13.
Crossref
Crossref
Jorseth Rodelo Gutiérrez, Arturo René Mendoza Salgado, Marcio De Ávila Arias, Homero San-Juan-Vergara, Wendy Rosales Rada & Carlos Mario Meléndez Gómez. (2022) Epigenetic Modulators as Treatment Alternative to Diverse Types of
Cancer. Current Medicinal Chemistry 29:9, pages 1503-1542.
Crossref
Crossref
Lu Feng, Guan Wang, Yi Chen, Gu He, Bo Liu, Jie Liu, Cheng‐Ming Chiang & Liang Ouyang. (2021) Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives. Medicinal Research Reviews 42:2, pages 710-743.
Crossref
Crossref
Judith López, Ana M. Añazco-Guenkova, Óscar Monteagudo-García & Sandra Blanco. (2022) Epigenetic and Epitranscriptomic Control in Prostate Cancer. Genes 13:2, pages 378.
Crossref
Crossref
Zaoqu Liu, Yuqing Ren, Siyuan Weng, Hui Xu, Lifeng Li & Xinwei Han. (2022) A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Misaki Yasuda, Ahmed G K Habib, Kanako Sugiura, Hossain Mohammad Shamim & Masaru Ueno. (2022) The fission yeast bromodomain protein Bdf2 is required for the growth of cells with circular chromosomes. Bioscience, Biotechnology, and Biochemistry 86:2, pages 224-230.
Crossref
Crossref
Martina Pierri, Erica Gazzillo, Maria Giovanna Chini, Maria Grazia Ferraro, Marialuisa Piccolo, Francesco Maione, Carlo Irace, Giuseppe Bifulco, Ines Bruno, Stefania Terracciano & Gianluigi Lauro. (2022) Introducing structure-based three-dimensional pharmacophore models for accelerating the discovery of selective BRD9 binders. Bioorganic Chemistry 118, pages 105480.
Crossref
Crossref
Tapan Sharma. 2022. Understanding Cancer. Understanding Cancer
149
158
.
Tapan Sharma. 2022. Understanding Cancer. Understanding Cancer
133
148
.
Colleen E. Quaas & David T. Long. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
469
492
.
Alan J. Knox, Rachel L. Clifford & Klaudia Kaczmarek. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine
326
333
.
Andrew J. Fritz, Mohammed El Dika, Rabail H. Toor, Princess D. Rodriguez, Stephen J. Foley, Rahim Ullah, Daijing Nie, Bodhisattwa Banerjee, Dorcas Lohese, Kirsten M. Tracy, Karen C. Glass, Seth Frietze, Prachi N. Ghule, Jessica L. Heath, Anthony N. Imbalzano, Andre van Wijnen, Jonathan Gordon, Jane B. Lian, Janet L. Stein & Gary S. Stein. 2022. Nuclear, Chromosomal, and Genomic Architecture in Biology and Medicine. Nuclear, Chromosomal, and Genomic Architecture in Biology and Medicine
339
373
.
Yazeed Sawalha. (2021) Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. Journal of Personalized Medicine 11:12, pages 1345.
Crossref
Crossref
Eui-Jun Kim, Peng Liu, Shengjie Zhang, Kristine Donahue, Yidan Wang, Jennifer L Schehr, Serena K Wolfe, Amber Dickerson, Li Lu, Lixin Rui, Xuehua Zhong, Kari B Wisinski, Min Yu, Aussie Suzuki, Joshua M Lang, Irene M Ong & Wei Xu. (2021) BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. Nucleic Acids Research 49:21, pages 12211-12233.
Crossref
Crossref
Yanan Li, Han Gong, Pan Wang, Yu Zhu, Hongling Peng, Yajuan Cui, Heng Li, Jing Liu & Zi Wang. (2021) The emerging role of ISWI chromatin remodeling complexes in cancer. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
María del Mar Noblejas-López, Cristina Nieto-Jiménez, Eva M. Galán-Moya, David Tebar-García, Juan Carlos Montero, Atanasio Pandiella, Miguel Burgos & Alberto Ocaña. (2021) MZ1 co-operates with trastuzumab in HER2 positive breast cancer. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Yuanyong Huang, Xiaoya Duan, Zhen Wang, Yimei Sun, Qingqing Guan, Li Kang, Qiao Zhang, Lan Fang, Jiwen Li & Jiemin Wong. (2021) An acetylation-enhanced interaction between transcription factor Sox2 and the steroid receptor coactivators facilitates Sox2 transcriptional activity and function. Journal of Biological Chemistry 297:6, pages 101389.
Crossref
Crossref
Oluwole B. Akawa, Opeyemi S. Soremekun, Fisayo A. Olotu & Mahmoud E.S. Soliman. (2021) Atomistic insights into the selective therapeutic activity of 6-(2,4-difluorophenoxy)-5-((ethylmethyl)pyridine-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one towards bromodomain-containing proteins. Computational Biology and Chemistry 95, pages 107592.
Crossref
Crossref
Angeles Carlos-Reyes, Marcos A. Muñiz-Lino, Susana Romero-Garcia, César López-Camarillo & Olga N. Hernández-de la Cruz. (2021) Biological Adaptations of Tumor Cells to Radiation Therapy. Frontiers in Oncology 11.
Crossref
Crossref
Michael Dickinson, Javier BrionesAlex F. Herrera, Eva González-BarcaNilanjan GhoshRaul Cordoba, Sarah C. RutherfordEirini BournazouEmily Labriola-TompkinsIzolda FranjkovicEvelyne ChesneJurriaan Brouwer-VisserKatharina LechnerBarbara BrennanEveline NüeschMark DeMarioDominik RüttingerMartin Kornacker & Martin Hutchings. (2021) Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances 5:22, pages 4762-4770.
Crossref
Crossref
Olga Gusyatiner, Pierre Bady, Minh D T Pham, Yvonne Lei, Jungyeon Park, Roy T Daniel, Mauro Delorenzi & Monika E Hegi. (2021) BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. Neuro-Oncology 23:10, pages 1680-1692.
Crossref
Crossref
Seo Yun Lee, Jae Jin Kim & Kyle M. Miller. (2021) Bromodomain proteins: protectors against endogenous DNA damage and facilitators of genome integrity. Experimental & Molecular Medicine 53:9, pages 1268-1277.
Crossref
Crossref
Dan Fang, Mu-Ru Wang, Jia-Lun Guan, Ying-Ying Han, Jia-Qi Sheng, De-An Tian & Pei-Yuan Li. (2021) Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway. Experimental Cell Research 406:2, pages 112727.
Crossref
Crossref
Jonathan T. Seal, Stephen J. Atkinson, Paul Bamborough, Anna Bassil, Chun-wa Chung, James Foley, Laurie Gordon, Paola Grandi, James R. J. Gray, Lee A. Harrison, Ryan G. Kruger, Jeanne J. Matteo, Michael T. McCabe, Cassie Messenger, Darren Mitchell, Alex Phillipou, Alex Preston, Rab K. Prinjha, Francesco Rianjongdee, Inmaculada Rioja, Simon Taylor, Ian D. Wall, Robert J. Watson, James M. Woolven, Anastasia Wyce, Xi-Ping Zhang & Emmanuel H. Demont. (2021) Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry 64:15, pages 10772-10805.
Crossref
Crossref
Weiye Zhao, Ying Xu, Yufan Wang, Dan Gao, Jasmine King, Yajie Xu & Fu-Sen Liang. (2021) Investigating crosstalk between H3K27 acetylation and H3K4 trimethylation in CRISPR/dCas-based epigenome editing and gene activation. Scientific Reports 11:1.
Crossref
Crossref
Danlin Sun, Anna S. Nikonova, Peishan Zhang, Alexander Y. Deneka, Mark E. Fitzgerald, Ryan E. Michael, Linda Lee, Anna C. Lilly, Stewart L. Fisher, Andrew J. Phillips, Christopher G. Nasveschuk, David A. Proia, Zhigang Tu & Erica A. Golemis. (2021) Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models. Molecular Cancer Therapeutics 20:8, pages 1367-1377.
Crossref
Crossref
Xavier Rovira-Clavé, Sizun Jiang, Yunhao Bai, Bokai Zhu, Graham Barlow, Salil Bhate, Ahmet F. Coskun, Guojun Han, Chin-Min Kimmy Ho, Chuck Hitzman, Shih-Yu Chen, Felice-Alessio Bava & Garry P. Nolan. (2021) Subcellular localization of biomolecules and drug distribution by high-definition ion beam imaging. Nature Communications 12:1.
Crossref
Crossref
Samuel P. Boyson, Cong Gao, Kathleen Quinn, Joseph Boyd, Hana Paculova, Seth Frietze & Karen C. Glass. (2021) Functional Roles of Bromodomain Proteins in Cancer. Cancers 13:14, pages 3606.
Crossref
Crossref
Anu Shilpa Krishnatry, Alexander Voelkner, Arindam Dhar, Marita Prohn & Geraldine Ferron‐Brady. (2021) Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model. CPT: Pharmacometrics & Systems Pharmacology 10:7, pages 709-722.
Crossref
Crossref
Harish Iyer, Abhipradnya B. Wahul, Annapoorna P. K., Bharvi S. Sawant & Arvind Kumar. (2021) A BRD’s (BiRD’s) eye view of BET and BRPF bromodomains in neurological diseases. Reviews in the Neurosciences 32:4, pages 403-426.
Crossref
Crossref
Christine S. W. Law & Keng Y. Yeong. (2021) Benzimidazoles in Drug Discovery: A Patent Review. ChemMedChem 16:12, pages 1861-1877.
Crossref
Crossref
Aaron R. Waddell, Haojie Huang & Daiqing Liao. (2021) CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. Cancers 13:12, pages 2872.
Crossref
Crossref
Hae In Choi, Ga Yeong An, Mina Baek, Eunyoung Yoo, Jin Choul Chai, Young Seek Lee, Kyoung Hwa Jung & Young Gyu Chai. (2021) BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4. Scientific Reports 11:1.
Crossref
Crossref
Daye Lee, Da-Yeon Lee, You-Son HwangHye-Ran SeoShin-Ai Lee & Jongbum Kwon. (2021) The Bromodomain Inhibitor PFI-3 Sensitizes Cancer Cells to DNA Damage by Targeting SWI/SNF. Molecular Cancer Research 19:5, pages 900-912.
Crossref
Crossref
Najla KfouryZongtai Qi, Briana C. PragerMichael N. Wilkinson, Lauren BroestlKristopher C. BerrettArnav Moudgil, Sumithra SankararamanXuhua ChenJason Gertz, Jeremy N. RichRobi D. Mitra & Joshua B. Rubin. (2021) Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. Proceedings of the National Academy of Sciences 118:16.
Crossref
Crossref
Vijay H. Masand, Meghshyam K. Patil, Nahed Nasser E. El-Sayed, Magdi E.A. Zaki, Zainab Almarhoon & Sami A Al-Hussain. (2021) Balanced QSAR analysis to identify the structural requirements of ABBV-075 (Mivebresib) analogues as bromodomain and extraterminal domain (BET) family bromodomain inhibitor. Journal of Molecular Structure 1229, pages 129597.
Crossref
Crossref
Jack Calder, Amy Nagelberg, Jennifer Luu, Daniel Lu & William W. Lockwood. (2021) Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4. Oncogenesis 10:3.
Crossref
Crossref
Karishma Patel, Paul D. Solomon, James L. Walshe, Daniel J. Ford, Lorna Wilkinson-White, Richard J. Payne, Jason K. K. Low & Joel P. Mackay. (2021) BET-Family Bromodomains Can Recognize Diacetylated Sequences from Transcription Factors Using a Conserved Mechanism. Biochemistry 60:9, pages 648-662.
Crossref
Crossref
Irene Ylivinkka & Sara A. Wickström. (2021) BETting against wound healing. Nature Chemical Biology 17:3, pages 233-235.
Crossref
Crossref
James A. Browne, Monali NandyMazumdar, Alekh Paranjapye, Shih-Hsing Leir & Ann Harris. (2021) The Bromodomain Containing 8 (BRD8) transcriptional network in human lung epithelial cells. Molecular and Cellular Endocrinology 524, pages 111169.
Crossref
Crossref
Storm Hassell‐Hart, Sarah Picaud, Raphael Lengacher, Joshua Csucker, Regis Millet, Gilles Gasser, Roger Alberto, Hannah Maple, Robert Felix, Zbigniew J. Leśnikowski, Helen J. S. Stewart, Timothy J. Chevassut, Simon Morley, Panagis Filippakopoulos & John Spencer. (2021) Probing BRD Inhibition Substituent Effects in Bulky Analogues of (+)‐JQ1. Helvetica Chimica Acta 104:3.
Crossref
Crossref
Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati, Khanh T. Do, Caron A. Jacobson, Ulka Vaishampayan, Amy Weise, Paolo F. Caimi, Joseph Paul Eder, Christopher A. French, Emily Labriola-Tompkins, Frédéric Boisserie, William E. Pierceall, Jianguo Zhi, Sharon Passe, Mark DeMario, Martin Kornacker & Philippe Armand. (2020) A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal of Cancer 124:4, pages 744-753.
Crossref
Crossref
A. Genthon, M. Killian, P. Mertz, P. Cathebras, S. Gimenez De Mestral, D. Guyotat & E. Chalayer. (2021) Les myélofibroses. La Revue de Médecine Interne 42:2, pages 101-109.
Crossref
Crossref
Yammy Yung, Emily Lee, Hiu-Tung Chu, Pui-Kwan Yip & Harinder Gill. (2021) Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. International Journal of Molecular Sciences 22:2, pages 659.
Crossref
Crossref
Frank Jühling, Nourdine Hamdane, Emilie Crouchet, Shen Li, Houssein El Saghire, Atish Mukherji, Naoto Fujiwara, Marine A Oudot, Christine Thumann, Antonio Saviano, Armando Andres Roca Suarez, Kaku Goto, Ricard Masia, Mozhdeh Sojoodi, Gunisha Arora, Hiroshi Aikata, Atsushi Ono, Parissa Tabrizian, Myron Schwartz, Stephen J Polyak, Irwin Davidson, Christian Schmidl, Christoph Bock, Catherine Schuster, Kazuaki Chayama, Patrick Pessaux, Kenneth K Tanabe, Yujin Hoshida, Mirjam B Zeisel, François HT Duong, Bryan C Fuchs & Thomas F Baumert. (2021) Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 70:1, pages 157-169.
Crossref
Crossref
Mohd. Muddassir, Kunjal Soni, Chetan B. Sangani, Abdullah Alarifi, Mohd. Afzal, Naaser A. Y. Abduh, Yongtao Duan & Poonam Bhadja. (2021) Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs. RSC Advances 11:2, pages 612-636.
Crossref
Crossref
Laura Marroqui, Atenea Alexandra Perez-Serna, Ignacio Babiloni-Chust & Reinaldo Sousa Dos Santos. 2021. Pancreatic ß-Cell Biology in Health and Disease. Pancreatic ß-Cell Biology in Health and Disease
1
80
.
Caroline Dix & Christian Bryant. 2021. Resistance to Targeted Therapies in Multiple Myeloma. Resistance to Targeted Therapies in Multiple Myeloma
129
145
.
Renato Paro, Ueli Grossniklaus, Raffaella Santoro & Anton WutzRenato Paro, Ueli Grossniklaus, Raffaella Santoro & Anton Wutz. 2021. Introduction to Epigenetics. Introduction to Epigenetics
151
177
.
Martin Hügle, Pierre Regenass, Robin Warstat, Mirjam Hau, Karin Schmidtkunz, Xavier Lucas, Daniel Wohlwend, Oliver Einsle, Manfred Jung, Bernhard Breit & Stefan Günther. (2020) 4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines. Journal of Medicinal Chemistry 63:24, pages 15603-15620.
Crossref
Crossref
Monica M. Mita & Alain C. Mita. (2020) Bromodomain inhibitors a decade later: a promise unfulfilled?. British Journal of Cancer 123:12, pages 1713-1714.
Crossref
Crossref
Feng Jiao, Ting Han, Cuncun Yuan, Yiyi Liang, Jiujie Cui, Meng Zhuo & Liwei Wang. (2020) Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. Cancer Cell International 20:1.
Crossref
Crossref
Andrei-Florian Stoica, Chao-Hui Chang & Siim Pauklin. (2020) Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells. Trends in Pharmacological Sciences 41:12, pages 977-993.
Crossref
Crossref
Sumera Zaib & Imtiaz Khan. (2020) Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges. Bioorganic Chemistry 105, pages 104425.
Crossref
Crossref
Zhiheng Li, Su Lin Lim, Yanfang Tao, Xiaolu Li, Yi Xie, Chun Yang, Zimu Zhang, You Jiang, Xianbing Zhang, Xu Cao, Hairong Wang, Guanghui Qian, Yi Wu, Mei Li, Fang Fang, Ying Liu, Mingcui Fu, Xin Ding, Zhenghong Zhu, Haitao Lv, Jun Lu, Sheng Xiao, Shaoyan Hu & Jian Pan. (2020) PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc. Frontiers in Oncology 10.
Crossref
Crossref
Marian Vincenzi, Flavia Anna Mercurio & Marilisa Leone. (2020) Protein Interaction Domains and Post-Translational Modifications: Structural Features and Drug Discovery Applications. Current Medicinal Chemistry 27:37, pages 6306-6355.
Crossref
Crossref
Kasturi Ranganna, Chelliah Selvam, Amruthesh Shivachar & Zivar Yousefipour. (2020) Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. International Journal of Molecular Sciences 21:21, pages 8198.
Crossref
Crossref
Jianru Zhang, Xiaoyun Zhang, Huidan Huang & Yimei Ding. (2020) A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II—Biological functions and inhibitors. Bioorganic Chemistry 104, pages 104318.
Crossref
Crossref
Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park & Giselle Saulnier Sholler. (2020) The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Cancer Medicine 9:21, pages 8144-8158.
Crossref
Crossref
Karishma Patel, Louise J. Walport, James L. Walshe, Paul D. SolomonJason K. K. Low, Daniel H. Tran, Kevork S. MouradianAna P. G. Silva, Lorna Wilkinson-White, Alexander NormanCharlotte FranckJacqueline M. MatthewsJ. Mitchell Guss, Richard J. Payne, Toby Passioura, Hiroaki Suga & Joel P. Mackay. (2020) Cyclic peptides can engage a single binding pocket through highly divergent modes. Proceedings of the National Academy of Sciences 117:43, pages 26728-26738.
Crossref
Crossref
Velten Horn, Seino A. K. Jongkees & Hugo van Ingen. (2020) Mimicking the Nucleosomal Context in Peptide-Based Binders of a H3K36me Reader Increases Binding Affinity While Altering the Binding Mode. Molecules 25:21, pages 4951.
Crossref
Crossref
Alessandro Allegra, Giovanni Pioggia, Alessandro Tonacci, Marco Casciaro, Caterina Musolino & Sebastiano Gangemi. (2020) Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm. Antioxidants 9:11, pages 1037.
Crossref
Crossref
Eiji Sugihara, Norisato Hashimoto, Satoru Osuka, Takatsune Shimizu, Sayaka Ueno, Shogo Okazaki, Tomonori Yaguchi, Yutaka Kawakami, Kenjiro Kosaki, Taka-Aki Sato, Shinichiro Okamoto & Hideyuki Saya. (2020) The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory Lymphoma. Cancer Research 80:20, pages 4439-4450.
Crossref
Crossref
Shauna L. French, Prakrith Vijey, Kyle W. Karhohs, Adrian R. Wilkie, Lillian J. Horin, Anjana Ray, Benjamin Posorske, Anne E. Carpenter, Kellie R. Machlus & Joseph E. ItalianoJr.Jr.. (2020) High‐content, label‐free analysis of proplatelet production from megakaryocytes. Journal of Thrombosis and Haemostasis 18:10, pages 2701-2711.
Crossref
Crossref
Seul Gi Park, Daye Lee, Hye-Ran Seo, Shin-Ai Lee & Jongbum Kwon. (2020) Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells. Scientific Reports 10:1.
Crossref
Crossref
Yi-Ru Chen, Su-Shan Ouyang, Yan-Ling Chen, Ping Li, Hui-Wen Xu & Sen-Lin Zhu. (2020) BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma. Aging 12:17, pages 17541-17567.
Crossref
Crossref
Songhui Xu, Lingling Fan, Hee-Young Jeon, Fengbo Zhang, Xiaolu Cui, McKayla B. Mickle, Guihong Peng, Arif Hussain, Ladan Fazli, Martin E. Gleave, Xuesen Dong & Jianfei Qi. (2020) p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. Cancer Research 80:15, pages 3074-3087.
Crossref
Crossref
Abdallah Turky, Ashraf H. Bayoumi, Adel Ghiaty, Adel S. El-Azab, Alaa A.-M. Abdel-Aziz & Hamada S. Abulkhair. (2020) Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects. Bioorganic Chemistry 101, pages 104019.
Crossref
Crossref
Qiong Duan, Fu-Lian Huang, Song-Ji Li, Kang-Zhi Chen, Li Gong, Jun Qi, Ze-Hua Yang, Tian-lun Yang, Fang Li & Chang-Qi Li. (2020) BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2. Neuropharmacology, pages 108255.
Crossref
Crossref
Linda Anna Michelle Kulka, Pia-Victoria Fangmann, Diana Panfilova & Heidi Olzscha. (2020) Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Ping Bai, Xiaoxia Lu, Yu Lan, Zude Chen, Debasis Patnaik, Stephanie Fiedler, Robin Striar, Stephen J. Haggarty & Changning Wang. (2020) Radiosynthesis and in vivo evaluation of a new positron emission tomography radiotracer targeting bromodomain and extra-terminal domain (BET) family proteins. Nuclear Medicine and Biology 84-85, pages 96-101.
Crossref
Crossref
Nihay Laham-Karam, Gaspar P. Pinto, Antti Poso & Piia Kokkonen. (2020) Transcription and Translation Inhibitors in Cancer Treatment. Frontiers in Chemistry 8.
Crossref
Crossref
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Phillippe A Cassier, Victor Moreno, Johann S de Bono, Sara Duckworth Harward, Geraldine Ferron-Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J Parr, Rabinder K Prinjha, Christopher L Carpenter, John Hilton, David S Hong, Naomi B Haas, Mark C Markowski, Arindam Dhar, Peter J O’Dwyer & Geoffrey I Shapiro. (2020) Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum 4:2.
Crossref
Crossref
Durga Khandekar & Venkataswarup Tiriveedhi. (2020) Role of BET Inhibitors in Triple Negative Breast Cancers. Cancers 12:4, pages 784.
Crossref
Crossref
Flor M Mendez, Felipe J Núñez, Maria B Garcia-Fabiani, Santiago Haase, Stephen Carney, Jessica C Gauss, Oren J Becher, Pedro R Lowenstein & Maria G Castro. (2020) Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. Neuro-Oncology 22:2, pages 195-206.
Crossref
Crossref
Storm Hassell-HartAndrew RuncieTobias KrojerJordan DoyleElla LinehamCory A. Ocasio, Brenno A. D. Neto, Oleg FedorovGraham MarshHannah MapleRobert Felix, Rebecca BanksAlessio Ciulli, Sarah PicaudPanagis FilippakopoulosFrank von DelftPaul Brennan, Helen J. S. StewartTimothy J. ChevassutMartin WalkerCarol AustinSimon MorleyJohn Spencer. (2019) Synthesis and Biological Investigation of (+)-JD1, an Organometallic BET Bromodomain Inhibitor. Organometallics 39:3, pages 408-416.
Crossref
Crossref
Michael J. Topper, Michelle Vaz, Kristen A. Marrone, Julie R. Brahmer & Stephen B. Baylin. (2019) The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology 17:2, pages 75-90.
Crossref
Crossref
Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao & Liang Liu. (2019) Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer. Frontiers of Medicine 14:1, pages 60-67.
Crossref
Crossref
Velten Horn & Hugo van Ingen. 2020. Chromatin and Epigenetics. Chromatin and Epigenetics.
Huihui Zhu, Tao Wei, Yong Cai & Jingji Jin. (2020) Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy. Molecules 25:3, pages 578.
Crossref
Crossref
P. Ann Boriack‐Sjodin. 2020. Structural Biology in Drug Discovery. Structural Biology in Drug Discovery
423
448
.
Sajad Ahmad Bhat, Shalini Kashipathi Sureshbabu, Chinna Susan Philip & Shubhada Chiplunkar. 2020. Epigenetics of the Immune System. Epigenetics of the Immune System
315
352
.
Yu Zhong Peng, Li Jun Yang, Hang Hong Lo, Betty Yuen Kwan Law & Vincent Kam Wai Wong. 2020. New Nanomaterials and Techniques for Tumor-targeted Systems. New Nanomaterials and Techniques for Tumor-targeted Systems
135
229
.
Tomohiro Kozako, Yukihiro Itoh, Shin-ichiro Honda & Takayoshi Suzuki. 2020. Approaching Complex Diseases. Approaching Complex Diseases
111
148
.
Valentina Maggisano, Marilena Celano, Rocco Malivindi, Ines Barone, Donato Cosco, Catia Mio, Chiara Mignogna, Salvatore Panza, Giuseppe Damante, Massimo Fresta, Sebastiano Andò, Diego Russo, Stefania Catalano & Stefania Bulotta. (2019) Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo. Cancers 12:1, pages 91.
Crossref
Crossref
Matthew Chung, Laura E. Teigen, Silvia Libro, Robin E. Bromley, Dustin Olley, Nikhil Kumar, Lisa Sadzewicz, Luke J. Tallon, Anup Mahurkar, Jeremy M. Foster, Michelle L. Michalski & Julie C. Dunning Hotopp. (2019) Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics. mSystems 4:6.
Crossref
Crossref
Yifei Yang, Pan Chen, Leilei Zhao, Fangqing Zhang, Huibin Zhang & Jinpei Zhou. (2019)
Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-
a
]pyrazin-8(7H)-one as Novel BRD4 Inhibitors
. ACS Medicinal Chemistry Letters 10:12, pages 1680-1685.
Crossref
Crossref
Jorden A. Johnson, Christos A. Nicolaou, Steven E. Kirberger, Anil K. Pandey, Haitao Hu & William C. K. Pomerantz. (2019) Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains. ACS Medicinal Chemistry Letters 10:12, pages 1648-1654.
Crossref
Crossref
Jacob Peedicayil. (2019) Pharmacoepigenetics and Pharmacoepigenomics: An Overview. Current Drug Discovery Technologies 16:4, pages 392-399.
Crossref
Crossref
Shino Murakami, Rui Li, Anusha Nagari, Minho Chae, Cristel V. Camacho & W. Lee Kraus. (2019) Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells. Molecular Cancer Research 17:12, pages 2356-2368.
Crossref
Crossref
Daiki Takahashi, Jun Moriyama, Tomoe Nakamura, Erika Miki, Eriko Takahashi, Ayami Sato, Takaaki Akaike, Kaori Itto-Nakama & Hirokazu Arimoto. (2019) AUTACs: Cargo-Specific Degraders Using Selective Autophagy. Molecular Cell 76:5, pages 797-810.e10.
Crossref
Crossref
Audrey Vincent, Aïcha Ouelkdite-Oumouchal, Mouloud Souidi, Julie Leclerc, Bernadette Neve & Isabelle Van Seuningen. (2019) Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies. World Journal of Stem Cells 11:11, pages 920-936.
Crossref
Crossref
Jill A Fahrner & Hans T Bjornsson. (2019) Mendelian disorders of the epigenetic machinery: postnatal malleability and therapeutic prospects. Human Molecular Genetics 28:R2, pages R254-R264.
Crossref
Crossref
Franck Da Silva, Guillaume Bret, Leandro Teixeira, Claudio F. Gonzalez & Didier Rognan. (2019) Exhaustive Repertoire of Druggable Cavities at Protein–Protein Interfaces of Known Three-Dimensional Structure. Journal of Medicinal Chemistry 62:21, pages 9732-9742.
Crossref
Crossref
Valentina Gambacorta, Daniela Gnani, Luca Vago & Raffaella Di Micco. (2019) Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Frontiers in Cell and Developmental Biology 7.
Crossref
Crossref
Corentin Bon, Diane Erdmann, Ludovic Halby & Paola Barbara Arimondo. (2019) Espoirs et promesses de la méthylation de l’ADN et des histones comme cibles anticancéreuses. Bulletin du Cancer 106:10, pages 823-833.
Crossref
Crossref
Jianping Hu, Chang-Qing Tian, Mohammadali Soleimani Damaneh, Yanlian Li, Danyan Cao, Kaikai Lv, Ting Yu, Tao Meng, Danqi Chen, Xin Wang, Lin Chen, Jian Li, Shan-Shan Song, Xia-Juan Huan, Lihuai Qin, Jingkang Shen, Ying-Qing Wang, Ze-Hong Miao & Bing Xiong. (2019) Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. Journal of Medicinal Chemistry 62:18, pages 8642-8663.
Crossref
Crossref
Anna Varizhuk, Ekaterina Isaakova & Galina Pozmogova. (2019) DNA G‐Quadruplexes (G4s) Modulate Epigenetic (Re)Programming and Chromatin Remodeling. BioEssays 41:9.
Crossref
Crossref
Paul Bamborough, Chun-wa Chung, Emmanuel H. Demont, Angela M. Bridges, Peter D. Craggs, David P. Dixon, Peter Francis, Rebecca C. Furze, Paola Grandi, Emma J. Jones, Bhumika Karamshi, Kelly Locke, Simon C. C. Lucas, Anne-Marie Michon, Darren J. Mitchell, Peter Pogány, Rab K. Prinjha, Christina Rau, Ana Maria Roa, Andrew D. Roberts, Robert J. Sheppard & Robert J. Watson. (2019) A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification. Journal of Medicinal Chemistry 62:16, pages 7506-7525.
Crossref
Crossref
Rui Traquete, Elizabeth Henderson, Sarah Picaud, Pedro M. S. D. Cal, Florian Sieglitz, Tiago Rodrigues, Rudi Oliveira, Panagis Filippakopoulos & Gonçalo J. L. Bernardes. (2019) Evaluation of linker length effects on a BET bromodomain probe. Chemical Communications 55:68, pages 10128-10131.
Crossref
Crossref
Andrea G. Cochran, Andrew R. Conery & Robert J. SimsIIIIII. (2019) Bromodomains: a new target class for drug development. Nature Reviews Drug Discovery 18:8, pages 609-628.
Crossref
Crossref
Shuai Wang, Dandan Shen, Lijie Zhao, Xiaohan Yuan, Jialing Cheng, Bin Yu, Yichao Zheng & Hongmin Liu. (2019) Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors. Chinese Chemical Letters.
Crossref
Crossref
Caroline R.M. Wiggers, Anita M.A.P. Govers, Daphne Lelieveld, David A. Egan, C. Michel Zwaan, Edwin Sonneveld, Paul J. Coffer & Marije Bartels. (2019) Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. Pediatric Blood & Cancer 66:8.
Crossref
Crossref
Jasmine Kaur, Abdelkader Daoud & Scott T. Eblen. (2019) Targeting Chromatin Remodeling for Cancer Therapy. Current Molecular Pharmacology 12:3, pages 215-229.
Crossref
Crossref
Robert Taylor, Jun Long, Joon Won Yoon, Ronnie Childs, Kathrine B. Sylvestersen, Michael L. Nielsen, King-Fu Leong, Stephen Iannaccone, David O. Walterhouse, David J. Robbins & Philip Iannaccone. (2019) Regulation of GLI1 by cis DNA elements and epigenetic marks. DNA Repair 79, pages 10-21.
Crossref
Crossref
Chong Wang, Sizun Jiang, Liangru Ke, Luyao Zhang, Difei Li, Jun Liang, Yohei Narita, Isabella Hou, Chen-hao Chen, Liangwei Wang, Qian Zhong, Yihong Ling, Xing Lv, Yanqun Xiang, Xiang Guo, Mingxiang Teng, Sai-Wah Tsao, Benjamin E. Gewurz, Mu-Sheng Zeng & Bo Zhao. (2019) Genome-wide CRISPR-based gene knockout screens reveal cellular factors and pathways essential for nasopharyngeal carcinoma. Journal of Biological Chemistry 294:25, pages 9734-9745.
Crossref
Crossref
Antonino Cattaneo & Michele Chirichella. (2019) Targeting the Post-translational Proteome with Intrabodies. Trends in Biotechnology 37:6, pages 578-591.
Crossref
Crossref
Michael Sebastian Ostertag, Wiebke Hutwelker, Oliver Plettenburg, Michael Sattler & Grzegorz Maria Popowicz. (2019) Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants. Journal of Molecular Biology 431:11, pages 2213-2221.
Crossref
Crossref
N. G. R. Dayan Elshan, Matthew B. Rettig & Michael E. Jung. (2018) Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain. Medicinal Research Reviews 39:3, pages 910-960.
Crossref
Crossref
Yang Liu & Stefan Klaus Barta. (2019) Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. American Journal of Hematology 94:5, pages 604-616.
Crossref
Crossref
Nunzio Del Gaudio, Antonella Di Costanzo, Ning Qing Liu, Lidio Conte, Antimo Migliaccio, Michiel Vermeulen, Joost H. A. Martens, Hendrik G. Stunnenberg, Angela Nebbioso & Lucia Altucci. (2019) BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death & Disease 10:5.
Crossref
Crossref
Iqra Muneer, Muhammad T. ul Qamar, Kishver Tusleem, Sadaf Abdul Rauf, Hafiz M.J. Hussain & Abdul R. Siddiqi. (2019) Discovery of selective inhibitors for cyclic AMP response element-binding protein. Anti-Cancer Drugs 30:4, pages 363-373.
Crossref
Crossref
Klaudia A. Kaczmarek, Rachel L. Clifford & Alan J. Knox. (2019) Epigenetic Changes in Airway Smooth Muscle as a Driver of Airway Inflammation and Remodeling in Asthma. Chest 155:4, pages 816-824.
Crossref
Crossref
Haitao Huang, Yuxuan Wang, Qin Li, Xiaoyan Fei, Haitao Ma & Rongkuan Hu. (2019) miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9. Cancer Letters 446, pages 81-89.
Crossref
Crossref
Renata L. Markman, Liana P. Webber, Carlos H. V. Nascimento Filho, Leonardo A. Reis, Pablo A. Vargas, Marcio A. Lopes, Virgilio Zanella, Manoela D. Martins, Cristiane H. Squarize & Rogerio M. Castilho. (2018) Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma. Cellular Oncology 42:2, pages 143-155.
Crossref
Crossref
Ye Chen, Liang Xu, Anand Mayakonda, Mo-Li Huang, Deepika Kanojia, Tuan Zea Tan, Pushkar Dakle, Ruby Yu-Tong Lin, Xin-Yu Ke, Jonathan W. Said, Jianxiang Chen, Sigal Gery, Ling-Wen Ding, Yan-Yi Jiang, Angela Pang, Mark Edward Puhaindran, Boon Cher Goh & H. Phillip Koeffler. (2019) Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nature Communications 10:1.
Crossref
Crossref
Samantha L. Goldman, Ciaran Hassan, Mihir Khunte, Arielle Soldatenko, Yunji Jong, Ebrahim Afshinnekoo & Christopher E. Mason. (2019) Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity. Frontiers in Genetics 10.
Crossref
Crossref
Mary E. White, Joelle M. Fenger & William E. CarsonIIIIII. (2019) Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cellular Immunology 337, pages 48-53.
Crossref
Crossref
Youjia Han, Sven Lindner, Yi Bei, Heathcliff Dorado Garcia, Natalie Timme, Kristina Althoff, Andrea Odersky, Alexander Schramm, Andrej Lissat, Annette Künkele, Hedwig E. Deubzer, Angelika Eggert, Johannes H. Schulte & Anton G. Henssen. (2019) Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Cancer Letters 445, pages 24-33.
Crossref
Crossref
Valentina Maggisano, Marilena Celano, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Valeria Pecce, Antonella Verrienti, Federica Baldan, Catia Mio, Lorenzo Allegri, Marianna Maranghi, Rosa Falcone, Giuseppe Damante, Diego Russo & Stefania Bulotta. (2019) Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells. Endocrine 63:3, pages 545-553.
Crossref
Crossref
Gianluca Sbardella. 2019. Epigenetic Drug Discovery. Epigenetic Drug Discovery
297
345
.
Jong Woo Park & Jeung-Whan Han. (2019) Targeting epigenetics for cancer therapy. Archives of Pharmacal Research 42:2, pages 159-170.
Crossref
Crossref
Sarah Sammons, Noah S. Kornblum & Kimberly L. Blackwell. (2018) Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Targeted Oncology 14:1, pages 1-12.
Crossref
Crossref
Adeyemi Rahman, Patrick O'Sullivan & Isabel Rozas. (2019) Recent developments in compounds acting in the DNA minor groove. MedChemComm 10:1, pages 26-40.
Crossref
Crossref
Namrata S. Chandhok & Thomas Prebet. (2019) Insights into novel emerging epigenetic drugs in myeloid malignancies. Therapeutic Advances in Hematology 10, pages 204062071986608.
Crossref
Crossref
Helen Loo Yau, Ilias Ettayebi & Daniel D. De Carvalho. (2019) The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. Trends in Cell Biology 29:1, pages 31-43.
Crossref
Crossref
Raghda Hassan, Salma N. Tammam, Sara El Safy, Mohammad Abdel-Halim, Anastasia Asimakopoulou, Ralf Weiskirchen & Samar Mansour. (2019) Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis. European Journal of Pharmaceutics and Biopharmaceutics 134, pages 96-106.
Crossref
Crossref
Nathan J. Dupper, Yingsheng Zhou, Jérôme Govin & Charles E. McKenna. 2019. Pharmacoepigenetics. Pharmacoepigenetics
475
492
.
Ramakrishnan Natesan, Shweta Aras, Samuel Sander Effron & Irfan A. Asangani. 2019. Prostate Cancer. Prostate Cancer
379
407
.
David Hanly, Manel Esteller & María Berdasco. 2020. Chemical Epigenetics. Chemical Epigenetics
401
428
.
William C. K. Pomerantz, Jorden A. Johnson & Peter D. Ycas. 2020. Chemical Epigenetics. Chemical Epigenetics
287
337
.
A. Ganesan. 2020. Chemical Epigenetics. Chemical Epigenetics
1
27
.
Terrence J. Bradley, Justin M. Watts & Ronan T. Swords. (2018) Leveraging Hypomethylating Agents for Better MDS Therapy. Current Hematologic Malignancy Reports 13:6, pages 507-515.
Crossref
Crossref
Rebecca S. DeVaux & Jason I. Herschkowitz. (2018) Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 23:4, pages 223-235.
Crossref
Crossref
Stephanie M. Jensen, Gregory K. Potts, Damien B. Ready & Melanie J. Patterson. (2018) Specific MHC-I Peptides Are Induced Using PROTACs. Frontiers in Immunology 9.
Crossref
Crossref
Majid Momeny, Haniyeh Eyvani, Farinaz Barghi, Seyed H. Ghaffari, Sepehr Javadikooshesh, Robab Hassanvand Jamadi, Fatemeh Esmaeili, Zivar Alishahi, Azam Zaghal, Davood Bashash, Fazel S. Samani, Parisa Ghaffari, Ahmad R. Dehpour, Seyyed M. Tavangar, Kamran Alimoghaddam & Ardeshir Ghavamzadeh. (2018) Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells. Anti-Cancer Drugs 29:10, pages 1011-1020.
Crossref
Crossref
Lihua Shi, Song Li, Kelly Maurer, Zhe Zhang, Michelle Petri & Kathleen E. Sullivan. (2018) Enhancer RNA and NFκB-dependent P300 regulation of ADAMDEC1. Molecular Immunology 103, pages 312-321.
Crossref
Crossref
Marina Baretti & Nilofer Saba Azad. (2018) The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer 42:6, pages 530-547.
Crossref
Crossref
Subhankar Biswas & C. Mallikarjuna Rao. (2018) Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy. European Journal of Pharmacology 837, pages 8-24.
Crossref
Crossref
Malay Mandal, Mark Maienschein-Cline, Patrick Maffucci, Margaret Veselits, Domenick E. Kennedy, Kaitlin C. McLean, Michael K. Okoreeh, Sophiya Karki, Charlotte Cunningham-Rundles & Marcus R. Clark. (2018) BRWD1 orchestrates epigenetic landscape of late B lymphopoiesis. Nature Communications 9:1.
Crossref
Crossref
Shreeya Bakshi, Christina McKee, Keegan Walker, Christina Brown & G. Rasul Chaudhry. (2018) Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells. Oncotarget 9:73, pages 33853-33864.
Crossref
Crossref
Tian Lu, Jun-chi Hu, Wen-chao Lu, Jie Han, Hong Ding, Hao Jiang, Yuan-yuan Zhang, Li-yan Yue, Shi-jie Chen, Hua-liang Jiang, Kai-xian Chen, Hui-fang Chai & Cheng Luo. (2018) Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay. Acta Pharmacologica Sinica 39:9, pages 1544-1552.
Crossref
Crossref
Alessandro Agnarelli, Tim Chevassut & Erika J. Mancini. (2018) IRF4 in multiple myeloma—Biology, disease and therapeutic target. Leukemia Research 72, pages 52-58.
Crossref
Crossref
Björn Tampe & Michael Zeisberg. (2018) Chromatin dynamics at the core of kidney fibrosis. Matrix Biology 68-69, pages 194-229.
Crossref
Crossref
Sarmistha Mitra & Raju Dash. (2018) Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors. Journal of Molecular Graphics and Modelling 83, pages 42-52.
Crossref
Crossref
Meghan E Breen & Anna K Mapp. (2018) Modulating the masters: chemical tools to dissect CBP and p300 function. Current Opinion in Chemical Biology 45, pages 195-203.
Crossref
Crossref
Sucharitha Iyer & Sunita K Agarwal. (2018) Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types. Journal of Molecular Endocrinology 61:1, pages R13-R24.
Crossref
Crossref
A. Ganesan. (2018) Epigenetic drug discovery: a success story for cofactor interference. Philosophical Transactions of the Royal Society B: Biological Sciences 373:1748, pages 20170069.
Crossref
Crossref
Displaying 200 of 208 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list